Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Explore linked clinical trials.6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of FZ-AD004 in Patients With Advanced Solid Tumors | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 | 2026-08-28 | NCT05914545 | |
| A Phase I Study of FZ-AD005 in Patients With High-Grade Glioma (HGG) | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Not yet recruiting | Phase 1 | 2026-03-06 | NCT07455045 | |
| A Study of FZ-AD005 in Patients With Advanced Solid Tumors | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 1 | 2026-03-04 | NCT06424665 | |
| A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin PDT | Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Port-Wine Stain, Skin Abnormalities, Skin and Connective Tissue Diseases, skin disorder | Recruiting | Phase 2 | 2026-03-03 | NCT05171894 | |
| A Study of FDA018-ADC in Patients With Advanced Solid Tumors | Advanced/ Metastatic Solid Tumors | Active, not recruiting | Phase 1 | 2026-01-23 | NCT05174637 | |
| FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 3 | 2026-01-22 | NCT06519370 |